La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Le cluster Dopamine - D2 Dopamine receptor

Terms

8Dopamine
4D2 Dopamine receptor
5Comparative study
2Low dose
2Depletion
2D3 Dopamine receptor
5Double blind study
2Dopa

Associations

Freq.WeightAssociation
33D2 Dopamine receptor - Dopamine
33Comparative study - D2 Dopamine receptor
22Dopamine - Low dose
22Depletion - Dopamine
22D3 Dopamine receptor - Dopamine
22D2 Dopamine receptor - Double blind study
22Dopa - Double blind study
22D2 Dopamine receptor - Dopa
22D2 Dopamine receptor - D3 Dopamine receptor
22Comparative study - Double blind study
22Comparative study - Dopamine
22Comparative study - Dopa

Documents par ordre de pertinence
000268 (2004) M. A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; P. Ravenscroft [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; M. J. Millan [France] ; J. M. Brotchie [Canada]Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate
000275 (2003) Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni]Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
000305 (2000) O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada]A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa
000253 (2006) Naomi P. Visanji [Canada] ; Mark J. Millan [France] ; Jonathan M. Brotchie [Canada]Actions at sites other than D3 receptors mediate the effects of BP897 on L-DOPA-induced hyperactivity in monoamine-depleted rats
000270 (2004) Howard T. J. Mount [Canada] ; Jean-Claude Martel [France] ; Paul Fluit [Canada] ; YINGJI WU [Canada] ; Eleanor Gallo-Hendrikx [Canada] ; Cristina Cosi [France] ; Marc R. Marien [France]Progressive sensorimotor impairment is not associated with reduced dopamine and high energy phosphate donors in a model of ataxia-telangiectasia
000277 (2003) Erwan Bezard [France] ; Christian E. Gross [France] ; Jonathan M. Brotchie [Canada]Presymptomatic compensation in Parkinson's disease is not dopamine-mediated
000280 (2003) Larissa Takser [France] ; Donna Mergler [Canada] ; Georgette Hellier [France] ; Josiane Sahuquillo [France] ; Guy Huel [France]Manganese, monoamine metabolite levels at birth, and child psychomotor development
000124 (2012) Bruno Dubois [France] ; Eduardo Tolosa [Espagne] ; Regina Katzenschlager [Autriche] ; Murat Emre [Turquie] ; Andrew J. Lees [Royaume-Uni] ; Günther Schumann [Allemagne] ; Emmanuelle Pourcher [Canada] ; Julian Gray [Suisse] ; Gail Thomas [Royaume-Uni] ; Jina Swartz [Royaume-Uni] ; Timothy Hsu [États-Unis] ; Margaret L. Moline [États-Unis]Donepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety study
000190 (2010) Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge V. Van De Witte [Pays-Bas] ; Guus Van Scharrenburg [Pays-Bas]Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease
000211 (2009) M. Mallar Chakravarty [Canada] ; Abbas F. Sadikot [Canada] ; Jürgen Germany [Canada] ; Pierre Hellier [France] ; Gilles Bertrand [Canada] ; D. Louis Collins [Canada]Comparison of Piece-Wise Linear, Linear, and Nonlinear Atlas-to-Patient Warping Techniques: Analysis of the Labeling of Subcortical Nuclei for Functional Neurosurgical Applications
000213 (2009) C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Robert Hauser [États-Unis] ; Paul D. Feigin [Israël] ; Joseph Jankovic [États-Unis] ; Anthony Lang [Canada] ; William Langston [États-Unis] ; Eldad Melamed [Israël] ; Werner Poewe [Autriche] ; Fabrizio Stocchi [Italie] ; Eduardo Tolosa [Espagne]A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
000239 (2007) M. Berk [Australie] ; S. Dodd [Australie] ; M. Kauer-Sant'Anna [Canada] ; G. S. Malhi [Australie] ; M. Bourin [France] ; F. Kapczinski [Brésil] ; T. Norman [Australie]Dopamine dysregulation syndrome : implications for a dopamine hypothesis of bipolar disorder
000242 (2006) Claire Ardouin [France] ; Valerie Voon [Canada] ; Yulia Worbe [France] ; Nehman Abouazar [France] ; Virginie Czernecki [France] ; Hassan Hosseini [France] ; Antoine Pelissolo [France] ; Elena Moro [Canada] ; Eugénie Lhommée [France] ; Anthony E. Lang [Canada] ; Yves Agid [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] ; Luc Mallet [France] ; Paul Krack [France]Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation
000314 (1999) I. Litvan [États-Unis] ; D. A. Grimes [Canada] ; A. E. Lang [Canada] ; Joseph Jankovic [États-Unis] ; A. Mckee [États-Unis] ; M. Verny [France] ; K. Jellinger [Autriche] ; K. R. Chaudhuri [Royaume-Uni] ; R. K. B. Pearce [Royaume-Uni]Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022